Clinical trial · Observational
Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer
Micro RNA's Associated With Lymph Node Metastasis in Endometrial Cancer
NCT01119573CI-TRIAL-00003589unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying at biomarkers in tissue samples from patients with stage I or stage III endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| microarray analysis | Genetic | — | UNRESOLVED |
| reverse transcriptase-polymerase chain reaction | Genetic | — | UNRESOLVED |
| RNA analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Association between microRNA expression and lymph node metastasis
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed endometrioid endometrial cancer * Stage IA, IB, IC, or IIIC disease * Any grade * Enrolled and evaluated on GOG-0210 Molecular Staging Study of Endometrial Cancer * Consented to allow their specimens and clinical data to be collected and stored for future research * Underwent complete surgical staging, including the following: * Hysterectomy * Bilateral oophorectomy * Washings as well as pelvic lymphadenectomy (sampling of four left and four right pelvic lymph nodes) * Para-aortic lymphadenectomy (sampling of one left and one right para-aortic lymph node) * Sufficient high-quality frozen primary tumor for testing with ≥ 75% tumor cellularity and ≤ 10% necrosis PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.